免疫抑制剂增加炎症性肠病患者淋巴瘤风险的Meta分析  

Immune inhibitors increase lymphoma risk in patients with inflammatory bowel disease：a meta-analysis

作　　者：黄艳[1] 甘华田[1] 

机构地区：[1]四川大学华西医院消化内科,成都610041

出　　处：《临床内科杂志》2014年第8期537-539,共3页Journal of Clinical Internal Medicine

基　　金：国家自然科学基资助项目金（No.81170369）

摘　　要：目的 探讨炎症性肠病（IBD）患者使用嘌呤类免疫抑制剂后发生淋巴瘤的风险.方法 检索1990年1月～2013年10月研究IBD患者使用硫唑嘌呤（AZA）或6-巯嘌呤（6-MP）后淋巴瘤发生风险的随机对照试验,按照纳入排除标准筛选文献,使用系统评价的方式对纳入的文献进行Meta分析.结果 本文共纳入9篇文献,共111 713例IBD患者.Meta分析结果显示,IBD患者使用嘌呤类免疫抑制剂后患淋巴瘤的风险比未使用患者的相对危险度（RR）增高了1.46倍（95％ CI1.04 ～2.05,P＜0.05）,经Begg秩检验和Egger＇s回归分析检验显示文献稳定性较好,不存在发表性偏倚.结论 IBD患者使用嘌呤类免疫抑制剂治疗后,患淋巴瘤的风险增加.Objective To investigate the risk of lymphoma in patients with inflammatory bowel disease after treatment with purine immunosuppressive agents. Methods All the randomized controlled studies about the risk of lymphoma in patients with inflammatory bowel disease after treatment with azathioprine（AZA） or 6-mereaptopurine（6 - MP） were investigated by searching the literatures in Chinese or English published between January 1990 and October ：2013. The pooled relative risk of lymphoma was analysed using meta-analysis. Results Nine trials including 111713 patients were recruited in our study. Meta-analysis showed that the relative risk（RR） of lymphoma was 1.46 （95% CI：1. 04-2.05,P 〈 0.05 ） and there were no publication bias. Conclusion The risk of lymphoma increases in IBD patients after treatment with purine immunosuppressive agents.

关 键 词：嘌呤类免疫抑制剂 炎症性肠病 淋巴瘤 META分析 

分 类 号：R195.1[医药卫生—卫生统计学]